Combinations with FLT3 inhibitors: the way forward for AML treatment
Description: The RATIFY trial (NCT00651261) showed that midostaurin, a FLT3 inhibitor that was a previously ineffective monotherapy for acute myeloid leukemia (AML), could improve survival when combined with other chemotherapies. In this interview, Katherine Smith of the University of California, San Francisco, CA, discusses how the immediate future of AML treatment appears to be the therapeutic combination of FLT3 inhibitors with other agents that target different pathways, in order to maximize efficacy. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
Shared By : VJHemOnc
Posted on : 12/06/17
Added : 1 month ago